Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT03765177
What this trial is testing

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

Who this might be right for
Acute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaChronic Lymphocytic Leukemia
Ottawa Hospital Research Institute 60
Not applicableUnknownNCT05176275
What this trial is testing

PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells

Who this might be right for
Lymphoma
The First Affiliated Hospital of Soochow University 10
Early research (Phase 1)Active Not RecruitingNCT04464200
What this trial is testing

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma+6 more
Memorial Sloan Kettering Cancer Center 30
Not applicableUnknownNCT02813837
What this trial is testing

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Who this might be right for
Leukemia, B-CellLymphoma, B-Cell
Innovative Cellular Therapeutics Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT05702853
What this trial is testing

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

Who this might be right for
B-cell Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Medical University of South Carolina 27
Not applicableUnknownNCT03423706
What this trial is testing

Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation

Who this might be right for
CD19-chimeric Antigen Receptor T CellsRelapsed and/or Refractory Acute Lymphoblastic Leukemiathe Haploidentical Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Harbin Medical University 50
Early research (Phase 1)UnknownNCT04250324
What this trial is testing

Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

Who this might be right for
Large B-cell Lymphoma
Shanghai Cell Therapy Group Co.,Ltd 21
Testing effectiveness (Phase 2)Looking for participantsNCT07003295
What this trial is testing

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Who this might be right for
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI) 20
Early research (Phase 1)Study completedNCT03144583
What this trial is testing

Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy

Who this might be right for
LeukemiaLymphoma
Sara V. Latorre 50
Very early researchNot Yet RecruitingNCT06879262
What this trial is testing

Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

Who this might be right for
R/R NHL
Tongji Hospital 60
Not applicableEnrolling By InvitationNCT07720310
What this trial is testing

Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus

Who this might be right for
System Lupus Erythematosus(SLE)
N.N. Alexandrov National Cancer Centre 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04404660
What this trial is testing

CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Autolus Limited 153
Testing effectiveness (Phase 2)WithdrawnNCT06153095
What this trial is testing

IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Who this might be right for
Systemic Lupus ErythematosusLupus Nephritis
Lyell Immunopharma, Inc.
Early research (Phase 1)UnknownNCT05333302
What this trial is testing

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaLymphoblastic B-Cell Lymphoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology 10
Testing effectiveness (Phase 2)UnknownNCT06149169
What this trial is testing

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Who this might be right for
Lymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd. 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04148430
What this trial is testing

Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Who this might be right for
B Cell ALLB-Cell LymphomaB-cell Non Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center 62
Testing effectiveness (Phase 2)Looking for participantsNCT03938987
What this trial is testing

Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapsed Non Hodgkin LymphomaRelapsed Adult ALLRelapsed Pediatric ALL
University of Alberta 63
Testing effectiveness (Phase 2)UnknownNCT03275493
What this trial is testing

CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaCD19 PositiveRelapse+1 more
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 40
Early research (Phase 1)UnknownNCT05420493
What this trial is testing

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd 54
Early research (Phase 1)UnknownNCT04194931
What this trial is testing

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University 20
Next Page